Literature DB >> 2993728

Diversity of melanoma plasma membrane proteinases: inhibition of collagenolytic and cytolytic activities by minocycline.

S Zucker, R M Lysik, N S Ramamurthy, L M Golub, J M Wieman, D P Wilkie.   

Abstract

The tissue-destructive proteinases of B16-BL6 melanoma cells from C57BL/6 mice and subcellular fractions were examined. Cancer cell organelles were isolated following nitrogen cavitation with the use of sucrose density gradient centrifugation. Serine, cysteine, and metalloproteinases were assayed with the use of radiolabeled proteins and synthetic substrates. Tumor-induced red blood cell lysis was quantitated by measurement of the release of isotope from 59Fe-labeled red blood cells (RBC) cocultivated with melanoma cells; the RBC were from Wistar rats. Enzyme inhibitors with specificity toward different classes of proteinases were used in the above assays to categorize the enzymes responsible for substrate degradation. Results indicated that intact melanoma cells, cell organelles, and cytosol contain proteinases that can degrade collagen and gelatin and lyse normal RBC. Melanoma plasma membranes are highly enriched in collagenase, gelatinase, cysteine proteinase, plasminogen activator, and cytolytic activity. The inhibition of tumor collagenolytic, gelatinolytic, and cytolytic activities by EDTA and 1,10-phenanthroline but not by diisopropyl fluorophosphate and N alpha-p-tosyl-L-lysine chloromethyl ketone indicates that metalloproteinases are the active enzymes in these assays. Minocycline, a synthetic tetracycline with demonstrable inhibitory activity with other mammalian collagenases, also inhibited melanoma collagenolytic and cytolytic activities.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993728

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis.

Authors:  R E Seftor; E A Seftor; J E De Larco; D E Kleiner; J Leferson; W G Stetler-Stevenson; T F McNamara; L M Golub; M J Hendrix
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

Review 3.  Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

4.  Purification and characterization of a connective-tissue-degrading metalloproteinase from the cytosol of metastatic melanoma cells.

Authors:  S Zucker; T Turpeenniemi-Hujanen; N Ramamurthy; J Wieman; R Lysik; P Gorevic; L A Liotta; S R Simon; L M Golub
Journal:  Biochem J       Date:  1987-07-15       Impact factor: 3.857

5.  The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism.

Authors:  S Gilbertson-Beadling; E A Powers; M Stamp-Cole; P S Scott; T L Wallace; J Copeland; G Petzold; M Mitchell; S Ledbetter; R Poorman
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Immunization with Porphyromonas (Bacteroides) gingivalis fimbriae protects against periodontal destruction.

Authors:  R T Evans; B Klausen; H T Sojar; G S Bedi; C Sfintescu; N S Ramamurthy; L M Golub; R J Genco
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

7.  beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.

Authors:  B A Teicher; E A Sotomayor; Z D Huang; G Ara; S Holden; V Khandekar; Y N Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.

Authors:  E A Sotomayor; B A Teicher; G N Schwartz; S A Holden; K Menon; T S Herman; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Authors:  B A Teicher; T T Korbut; K Menon; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Doxycycline suppression of ischemia-reperfusion-induced hepatic injury.

Authors:  J R Smith; W L Gabler
Journal:  Inflammation       Date:  1994-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.